Thursday 6th October 2005

8:30 - Registration and Welcome Address

SESSION 1: Anti-Inflammatory Drugs: Molecules and Mechanisms of Action

Chairmen: Pr Roderick Flower, Pr John Wallace and Pr Marvin Edeas

9:00 - Economic Impact of Anti-Inflammatory Drugs

What marketshare do anti-inflammatory drugs have in France, in Europe and world wide?
What are the most used anti-inflammatory drugs and for which pathologies?
What economic impacts did the problems surrounding the two anti-inflammatory drugs of the coxibs familly in 2004 have?
What are the latest trends in the anti-inflammatory drug market?

Mrs Katia Musitu, IMS Health, London, UK

9:45 - Inflammation and Anti-Inflammatory Drugs : General Presentation
History: from the Willow tree bark to present day
The different classes of anti-inflammatory drugs:

The traditional anti-inflammatory drugs: corticosteroids, non steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase 2 (COX2) inhibitors...
The emerging anti-inflammatory drugs: COX/lipoxygenase inhibitors, nitric oxide-releasing non steroidal anti-inflammatory drugs, antibodies directed against specific molecules involved in the inflammatory reaction...

What impact have anti-inflammatory drugs had on public health throughout the years?
Pr Roderick Flower, William Harvey Research Institute, London, UK - ABSTRACT

10:30 - Break

11:00 - Mechanisms of Action of the Synthetic Anti-Inflammatory Drugs
Inhibition of ecosanoides synthesis: inhibition of COX1 and COX2, inhibition of phospholipase A2, inhibition of lipoxins synthesis (LXs)…
COX-independent mechanisms: activation or inhibition of peroxisome proliferator-activated receptors (PPARs), inhibition of NFκB, inhibition of the BCL-XL gene expression...
Dr Pascal Eschwege, Department of Urology Hôpital Bicêtre, Le Kremlin Bicêtre, France - ABSTRACT

11:45 - Latest Advances in the Anti-Inflammatory Treatment of Rheumatoid Arthritis
Presentation and pathogenesis of RA.
What are the current anti-inflammatory therapies to treat this pathology ?

Non steroidal anti-inflammatory drugs and COX-2 inhibitors
Classical Disease modifying antireuhmatic drugs (DMARDs): glucocorticoïdes, sulphasalazine...
Biological DMARDs : anti-TNFα therapies, anti-IL1 therapies (antagonists of IL1-R)...
matrix metallo-proteinases (MMPs) inhibitors
interleukine 1 converting enzyme (ICE) inhibitors
kinases inhibitors : p38 MAPK, c-jun N-terminal kinase
new inflammatory cytokines inhibitors and other potential targets (IL-1 trap, anti-IL-17…)

Pr Pierre Miossec, Université de Lyon, Lyon, France - ABSTRACT

12:30 - Lunch

SESSION 2: Anti-Inflammatory Drugs and Main Inflammatory Diseases

Chairmen: Pr Pierre Miossec, Pr Gerd Bouma, Dr Michel Chignard

14:00 - Mechanisms of Action of the Biological Anti-Inflammatory Drugs
Antibodies against cytokines or other actors involved in inflammation.
Sens and antisens oligonucleotides, interference RNA (RNAi).
Dr Jacques Morel, Department of Immuno-Rhumatology, Lapeyronnie Hospital, Montpellier, France - ABSTRACT

14:45 - Latest Advances in the Anti-Inflammatory Treatment of Inflammatory Bowel Disease
Presentation and pathogenesis of inflammatory bowel diseases : Crohn’s disease, ulcerative colitis...
What are the current anti-inflammatory therapies to treat these pathologies ?

anti-TNFα therapies
anti-intégrines therapies
Thérapies based on apoptosis induction : anti-IL-12 antibodies…
Release of IL10 or TGFβ on the inflammatory site
Nucleotide–binding oligomerization domain 2 (NOD2), a new target?

Dr Gerd Bouma Department of Immunogenetics, Vrije Universiteit Medical Center, Amsterdam, The Netherlands - ABSTRACT

15:30 - Break

16:00 - Latest Advances in the Anti-Inflammatory Treatment of Airway Inflammation
Presentation and pathogenesis of inflammatory airway inflammations: asthma, chronic obstructive pulmonary disease (COPD)...
What are the current anti-inflammatory therapies to treat these pathologies ?

• Therapies based on glucocorticoides.
Anti-leukotrienes and inhibitors of 5-lipoxygenase (5-LO).
Anti-cytokines and anti-chemokines therapies.
Inhibitors and activators of PPARs.
Cellular adhesion molecule inhibition.
Antisens therapies: respirable antisens oligonucleotides

Pr Neil Barnes, The London Chest Hospital, London,UK

16:45 - Latest Advances in the Anti-Inflammatory Treatment of Cardio-Vascular Disease
Presentation and pathogenesis of inflammatory cardiovascular diseases: atherosclerosis, coronary artery disease...
What are the current anti-inflammatory therapies to treat these pathologies ?
What are the new pathways that could be used to develop new treatments for these pathologies?

Inhibitors and activators of PPARs
Liver X receptors (LXRs) agonists
MMPs inhibitors
Cellular adhesion molecule inhibition

Pr Mustapha Rouis, Institut Pasteur de Lille, Lille, France - ABSTRACT

17:30 - End of the Day

20:00 - Gala Dinners

Friday 7th October 2005

Chairmen : Pr Jari Koistinaho, Pr Christopher Griffiths and Pr Thomas Simmet

9:00 - Oxydative Stress and Inflammation: What Roles for Antioxidants as Anti-Inflammatory Drugs?
What are the mechanisms of action of antioxidants: inhibition of NFκB, decrease of inflammatory cytokine expression, re-establishment of the cellular redox state?
Potential role of antioxidants as anti-inflammatory drugs: example of the superoxyde dismutase (SOD) and polyphenols
Pr Marvin Edeas, President of the French Society of Antioxidants, Paris, France - ABSTRACT

9h20 - Phenolic Antioxidants, anti-inflammatory/anticancer properties and Structure activities studies
Dr Fernanda Borges, Univesity of Porto, Portugal - ABSTRACT

9:45 - Side Effects of Anti-Inflammatory Drugs
Effects on the gastro-intestinal tract
Effects on the liver
Side effects of COX 2 inhibitors on the cardio-vascular system
What are the various strategies to decrease the side effects of anti-inflammatory drugs?
Pr John Wallace, University of Calgary, Calgary, Alberta, Canada - ABSTRACT

10:30 - Break

11:00 - How can We Evaluate the Efficiency of an Anti-Inflammatory Drug?
In vitro tests, in vivo tests: What models currently exist?
What are their limits and weaknesses?
Which models are the most efficient at the moment?
Are new models being developed?
Pr Jean Pierre Pujol, University of Caen, France - ABSTRACT

SESSION 3 : Innovations and Perspectives in Anti-Inflammatory Therapies

11:45 - When Inflammation Leads to Cancer
What are the correlations between inflammation and cancer?
What role do the IKK NFκB system and toll-like receptors (TLRs) play?
What new treatment perspectives can arise from the involvement of these molecules?
Dr Alain Chariot, University of Liege, Liege, Belgium - ABSTRACT

12:30 - Lunch

Chairmen : Dr Pascal Eschwege, Dr Alain Chariot, Pr Mustapha Rouis

14:00 - Anti-Inflammatory Drugs and Neurodegenerative Diseases
Presentation and pathogenesis of inflammatory neurodegenerative diseases: Alzheimer’s disease, multiple sclerosis...
What therapies can be used in these pathologies?
Pr Jari Koistinaho, AI Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland - ABSTRACT

14:20 - Anti-Inflammatory Drugs and Dermatological Diseases
Presentation and pathogenesis of inflammatory dermatological diseases: psoriasis, psoriatic arthritis...
What therapies can be used in these pathologies?
Anti-cytokine therapies: IL-1 and IL-1R, TNFα, IL-23, IFNγ…
Pr Christopher Griffiths, University of Manchester, Manchester, UK - ABSTRACT

14:40 - Anti-Inflammatory Drugs and Veterinary Medicine
The Veterinary Market
Main pathologies requiring the use of AI drugs in domestic animals and differences with human medicine: in dogs, in cats, in horses and in cattle
Products used in the veterinary field (with or without veterinary MA)
Regulatory issues
Dr Fabrice Thoulon, Vétoquinol, Magny Vernois, France - ABSTRACT

15:00 - Natural Anti-Inflammatory Drugs: Recent Developments
What are the most promizing products to cure inflammatory diseases? Clinical evidences
What are the mechanisms of action of natural anti-inflammatory drugs? Example of the triterpenoids
What are the perspectives for these molecules?
Pr Thomas Simmet, University of Ulm, Ulm, Germany - ABSTRACT

15h35 - Break

SESSION 4: Latest Pharmaceutical Innovations in the Anti-Inflammatory Field

16:00 - What Are the Latest Innovations in the Anti-Inflammatory Drug Field: Presentations by Pharmaceutical Laboratories and Start-Ups (10 minutes to convince)

Systemic low dose antisense delivery and anti-inflammatory effect using Smarticles® vectors
Dr. Una Rauchhaus, Novosom AG, Germany - ABSTRACT
Signaling Pathways and the Future of Anti-inflammatory Drugs
Alan Lewis, Celgene, San Diego, CA - ABSTRACT
Anti-Inflammatory and Anti-Arthritic Activity of 2-Methoxyestradiol In A Rat Model Of Collagen-Induced Arthritis
Dr. Ernest Brahn, EntreMed - ABSTRACT
Inhibition of acute and chronic lung inflammation by a novel PDE 4 inhibitor
Dr. Bernhard Ryffel, CNRS, IEM2815, Orléan, France - ABSTRACT
Evaluation of Statin in Decreasing the Early Mortality and Morbidity of Acute Coronary Syndrome : a clinical trial
Dr. Shahmohammadi Mousavi, Rajaie Cardiovascular Medical and Research Center, Iran - ABSTRACT
Modulation of human lymphocyte functions in vitro by a prostanoid EP2 receptor agonist.
Dr. J.G. Zhang, Pharmagene Laboratories Ltd, UK - ABSTRACT

17:00 - Round Table Discussion : Anti-Inflammatories of the Future, Myth or Reality?
(In the Presence of the Scientific Comittee)

Anti-Inflammatory Drugs 2005 Innovation Award
The scientific committee will name the most innovative project upon oral or poster presentation

Film Projection : Pasteur (32 min)